Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obinutuzumab (Primary) ; Diphenhydramine; Methylprednisolone; Paracetamol; Tacrolimus
  • Indications Membranous glomerulonephritis
  • Focus Registrational; Therapeutic Use
  • Acronyms MAJESTY
  • Sponsors Roche

    • Most Recent Events

    • 08 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 05 Jan 2024 Planned End Date changed from 1 May 2027 to 29 Dec 2027.
    • 05 Jan 2024 Planned primary completion date changed from 9 Jan 2025 to 29 Dec 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top